INTRODUCTION
In 1971, President Richard Nixon of the United States signed the National Cancer Act, which formally declared war on cancers. Billions of dollars have since been invested in research and development in order to better understand the mechanisms of cancer biology and to find more effective diagnostics and treatments. As a result, great strides have been made in every phase of cancer research, diagnosis and treatment, in particular for several specific types of cancers. Among many achievements, early detections, new drug therapeutics, surgical removal of tumors and other technologies have significantly increased the survival rates of cancer patients. However, despite this progress, the war has not yet been won and cancers are still the number one killer in the United States.
With the rapid expansion of research in genomics and proteomics during the last two decades, scientists now believe that cancer is close to being conquered. Genomics and proteomics are the studies of entire genomes of organisms at DNA, RNA and protein levels. Genomics at the DNA level is concerned with studies such as sequencing entire genomes and identifying mutations and single nucleotide polymorphisms (SNPs), which can be used as biomarkers in disease diagnoses, personalized medicine and treatments. On the other hand, proteomics involves investigation of proteins. Between DNA and proteins, the accumulation of genome knowledge has incited studies into functional genomics or gene expression at the RNA level. As a result of these studies, microarray, antibody array, protein array and next-generation sequencing have been developed in order to meet the requirements for high throughput approaches that can identify the bio-molecules that are specifically expressed in diseases such as cancers. Consequently, methods such as the classic and commonly used blood tests for detection of just a few proteins and biochemical molecules at a time have rapidly evolved into modem molecular and cellular biology tools that have spurred the discovery of biomarkers at several levels by a parallel high-throughput approach. Publications on genome sequences, mutations, SNPs, mRNAs, microRNA, non-coding RNAs and proteins have exploded in the last two decades. Even chimeric RNAs, one particular domain of biomarkers that had been until recently overlooked, seems to be gaining prominence. A chimeric RNA is a RNA molecule that is made of two or more pieces of RNAs from different loci that should not be found on the same molecule. Chimeric RNAs are initially identified from transcripts of fusion genes due to chromosome translation, inversion or deletion (Table 1) . Further studies have indicated that many other RNA chimeras are generated from mechanisms such as transcription read-through and splicing, transcription of short homologous sequence slippage or from so called trans-splicing (Table 1 
CHIMERIC RNAs PRODUCED FROM FUSION GENES
A fusion gene is defined as a gene that is produced from two previously separated genes. It has been demonstrated that many cancers such as prostate cancers and hematological cancers involve fusion genes as a result of chromosomal translocation, interstitial deletions or chromosomal inversions. One of the best known examples is the fusion Bcr-Abl gene that is defined in the Philadelphia chromosome, a specific reciprocal chromosomal translocation between chromosomes 9 and 22 that is responsible for chronic myelogenous leukemia (CML) (9). This translocation results in an elongated chromosome 9 and a truncated chromosome 22. Consequentially, the fusion gene is formed by the Abl gene on chromosome 9 (region q34) to a part of the Bcr gene on chromosome 22 (region q11). Depending on the precise fusion sites between the Bcr gene and the Abl gene and on alternative splicing events, the oncogenic fusion gene produces proteins with molecular weights ranging from 185 to 210 kDa. Since more than 95% of CML patients have the Philadelphia chromosome, the presence of this translocation and the fusion Bcr-Abl gene has been widely used as a test to detect the disease. Fusion genes can be also formed from interstitial deletions. For instance, in a recent study (10), Santo et al. analyzed a series of neuroblastomas by comparative genomic hybridization and single-nucleotide polymorphism arrays and identified small interstitial deletions at 11q23, upstream of the forkhead-box R1 transcription factor (FOXR1) gene. These deletions lead to fusions between the genes at the proximal side of the deletions and the FOXR1 gene. More significantly, in contrast to the normal expression pattern of the FOXR1 gene that occurs in early embryogenesis, the resulting fusion transcripts of MLL-FOXR1 and PAFAH1B2-FOXR1 are exclusively expressed in neuroblastomas, indicating that the fusion products play a role in tumorigenesis of neuroblastomas. Chromosome inversion is another source that can produce fusion genes. Chromosome inversion takes place when a segment of a chromosome is reversed end to end. Fusion genes that are created from chromosome inversion have been described in numerous tumors. For example, the chromosome inversion inv(2)(p21;p23) that leads to the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene was identified in non-small cell lung cancer (NSCLC) (11). Other examples of fusion genes that result from chromosome inversion include the MLL (MixedLineage Leukemia) gene (12) with an inversion of 11q (inv (11) (q14q23)), producing a fusion gene of the MLL gene to the CALM (Clathrin Assembly Lymphoid Myeloid Leukemia); the inv(16) fusion gene CBFB-MYH11 (13); the NUP98-DDX10 fusion gene from the inversion (11) (p15q22) (14) and many others. It is unclear how many fusion genes there are in the human genome. But it appears that chromosome rearrangements that lead to chromosome translocations, inversions or deletions occur quite frequently and that these events may play an important role in evolution. Most fusion loci may not be transcribed. Therefore the direct effects of these translocations, inversions or deletions would be minimal if any. However, it has been shown that a fraction of fusion genes are transcribed and produce chimeric RNA molecules that are made of RNAs from two or more genes. In fact, many so-called "fusion genes" in cancer cells (15) are initially discovered not based on the fusion genes themselves at the genome DNA level but rather on identification of their fusion RNA products using the RT-PCR approach that detects fusion cDNAs in various cases, without necessarily confirming the existence of a corresponding gene in the cell genome (16, 17) . With the expansion of expressed sequence tag (EST) and cDNA databases and improvement of next generation sequencing technologies, an increased number of fusion RNAs and fusion genes have been identified and validated in recent years (2-4), especially in cancers. However, although it is commonly understood that fusion genes in cancers play a role in tumorigenesis, the mechanisms of this remain unclear. One explanation as to why fusion genes can cause tumors is that a fusion product from two or more genes
